EU/3/19/2189

About

On 21 August 2019, orphan designation EU/3/19/2189 was granted by the European Commission to Clinical Network Services (NL) B.V, the Netherlands, for gallium citrate for the treatment of cystic fibrosis.

Key facts

Active substance
gallium citrate
Disease / condition
Treatment of cystic fibrosis
Date of first decision
21/08/2019
Outcome
Positive
EU designation number
EU/3/19/2189

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Clinical Network Services (NL) B.V.
De Cuserstraat 93
1081 CN Amsterdam
Noord-Holland
The Netherlands
Tel. +31 2089 49169
E-mail: cns@clinical.net.au

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating